5-methoxycarbonylamino-n-acetyltryptamine

**5-methoxycarbonylamino-n-acetyltryptamine** (5-MCA-NAT) is a synthetic derivative of melatonin. It was initially described as a selective ligand for the MT3 melatonin binding site, but more recent molecular and cellular pharmacological studies have shown that it acts as a partial agonist at the MT1 and MT2 melatonin receptors in the sub-micromolar range. 5-MCA-NAT demonstrates affinity in the micromolar range for MT1 and MT2 receptors and lacks activity at quinone reductase 2 (MT3), despite early reports. The compound has been studied primarily for its intraocular hypotensive effects and potential use in lowering intraocular pressure (IOP) in animal models, specifically in rabbits and monkeys. It is being explored for ophthalmic administration, often in liposomal or mucoadhesive polymer formulations to enhance ocular bioavailability and effect[2][3][4][5][6][7].

Other names

5-methoxycarbonylamino-n-acetyltryptamine5-methoxy-carbonylamino-N-acetyltryptamine